Actively Recruiting
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-03-03
120
Participants Needed
1
Research Sites
177 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
CONDITIONS
Official Title
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent before any study procedures
- Age between 18 and 75 years at time of consent
- Histologically or cytologically confirmed solid tumors
- At least one measurable lesion per RECIST 1.1 criteria
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
- Adequate organ function
- Use of highly effective contraception for both genders of child-bearing potential from consent until 8 months after last dose
You will not qualify if you...
- Active central nervous system metastasis
- History of malignant tumors within 5 years before first dose
- Uncontrolled cancer pain
- Severe cardiovascular disease
- Clinically significant bleeding
- Uncontrolled pleural, peritoneal, or pericardial effusion
- Suspected interstitial lung disease
- Serious infection within 4 weeks before first dose
- Known HIV, active hepatitis B or C infection
- Unresolved adverse events from prior antineoplastic therapy greater than grade 1
- Received anti-cancer treatment within 4 weeks prior to first dose
- Major surgery within 4 weeks prior to first dose
- Planned or received live vaccines within 28 days before first dose
- Pregnancy, lactation, or planned pregnancy during study
- Allergy to investigational drug components
- Alcohol or drug abuse, serious medical or mental illness affecting safety or data
- Other conditions judged by investigator to affect study results or procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China, 250117
Actively Recruiting
Research Team
W
Wei Hou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here